Evuzamitide PET-CT Imaging for Detection of Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans

NIH has registered a new observational clinical trial on ClinicalTrials.gov. The study investigates whether PET-CT imaging using evuzamitide can identify transthyretin cardiac amyloidosis in patients whose standard nuclear scintigraphy is non-diagnostic but who exhibit elevated TAD1 blood levels. Participants meeting eligibility criteria will undergo a single PET-CT scan with evuzamitide and be followed for approximately 28 days to assess safety and collect additional clinical information.

For compliance professionals and clinical operations teams, this trial registration represents an informational event rather than a regulatory action. It does not impose new reporting, labeling, or quality obligations on sponsors, manufacturers, or healthcare providers. Organizations involved in cardiac amyloidosis diagnostics or radiopharmaceutical development may wish to monitor trial outcomes as preliminary evidence regarding evuzamitide's diagnostic utility may inform future clinical and regulatory considerations.